

1 **SUPPLEMENTARY INFORMATION**

2
3 **Plant-expressed cocaine hydrolase variants of butyrylcholinesterase**
4 **exhibit altered allosteric effects of cholinesterase activity and**
5 **increased inhibitor sensitivity.**
6

7 **Katherine E Larrimore^{1,†}, I. Can Kazan², Latha Kannan¹, R. Player Kendle^{1,‡},**
8 **Tameem Jamal¹, Matthew Barcus^{1,^}, Ashini Bolia^{2,*},**
9 **Stephen Brimijoin³, Chang-Guo Zhan⁴, S. Banu Ozkan², and Tsafirir S Mor^{1,*}**

10 ¹School of Life Sciences and Center of Immunotherapy, Vaccines, and Virotherapy,
11 Biodesign Institute, Arizona State University, Tempe, AZ 85287-4501, USA

12 ²Department of Physics and Center for Biological Physics, Arizona State University
13 Tempe, AZ 85287-1504, USA

14 ³Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic,
15 Rochester, MN 55905, USA

16 ⁴Molecular Modeling and Biopharmaceutical Center and Department of Pharmaceutical
17 Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA

18 [†]Current Address: Temasek Life Sciences Laboratory, National University of Singapore,
19 Singapore 117604

20 [‡]Current Address: Department of Botany, College of Letters and Sciences, University of
21 Wisconsin Madison, Madison, WI 53706, USA

22 [^]Current Address: Department of Animal Science, College of Agriculture and Life
23 Sciences, Cornell University, Ithaca, NY 14853, USA

1 ‡ Current Address: ARUP Labs, Salt Lake City, UT 84108, USA

2 *To whom correspondence should be addressed:

3 School of Life Sciences and The Biodesign Institute

4 P.O. Box 874501

5 Arizona State University

6 Tempe, AZ 85287-4501, USA

7 Tel: 1-480-727-7405; Fax: 1- 480-965-6899

8 Email: tsafir.mor@asu.edu

9

10

11

12

13

Supplementary material includes:

14 1. Figure Legends for Supplementary Figures S1 and S2

15 2. Supplementary Table S1 and Table S2

16 3. Supplementary Figures S1 and S2

17

1 **Legends for Supplementary Figures**

2 **Supplementary Figure S1. Schematic diagrams describing the kinetics of** 3 **cholinesterase-catalyzed hydrolysis of substrates**

4 (a) Scheme 1 describes the reaction of cholinesterase (E)-catalyzed hydrolysis of
5 substrates (S). K_{ss} is the dissociation constant of the peripheral site. The hydrolysis
6 capacity (bK_{cat}) reflects the allosteric effect of substrate binding at the peripheral binding
7 site. (b) Scheme 2 describes the reaction in terms of uncompetitive substrate
8 inhibition/activation and cooperative substrate binding with characteristic Hill coefficients
9 n and x that describe cooperativity or anticooperativity

10 **Supplementary Figure S2. Modeling of wild type and mutant by using Elastic** 11 **Network Model (ENM)**

12 WT human BChE and BChE_{V4} are modeled by ENM. The spheres indicate the locations
13 of alpha-carbons of each amino acid and the sticks are representing the harmonic
14 oscillators (i.e. springs) between them. The thickness of the sticks represents the
15 magnitude of the spring constant. For WT hBChE the mutation positions are shown as
16 blue spheres (A199, F227, S287, A328, and Y332) and for the pentavalent mutant
17 BChE_{V4} the mutation positions are shown as red spheres (S199, A227, G287, W328,
18 and G332). The spring constant for each connection is assumed to be same for the WT
19 (i.e. the thickness of the blue sticks is same as grey sticks). The mutation at a given
20 position are considered to destabilize the interactions of the mutational site. This is
21 incorporated in the model as a decrease in spring constant (low thickness values are
22 shown as red sticks indicating a loss in interaction strength with mutated positions).

23

1 **Supplementary Table S1**

2

3

4

5

Table S1. Cocaine hydrolase variants of butyrylcholinesterase used in this study.

Name	Amino acid mutations	References
pBChE _{V2}	F227A/S287G/A328W/Y332A	Pancook, <i>et al.</i> 2003
pBChE _{V3}	A199S/S287G/A328W/Y332G	Pan, <i>et al.</i> 2005
pBChE _{V4}	A199S/F227A/S287G/A328W/Y332G	Xue, <i>et al.</i> 2013
pBChE _{V5}	F227A/S287G/A328W/Y332G	Brimijoin and co-workers, unpublished

6

7

8

1 **Supplementary Table S2**

2

3

4

5

Table S2. Oligonucleotides used for site-directed mutagenesis. Forward (F) and reverse (R) primers are shown with mutation sites indicated in lowercase.

Name	Primer Sequence	Mutation
oTM607	(F) 5'CTTTGGAGAGTCTtctGGAGCTGCTTCTG ^{3'}	A199S
oTM608	(R) 5'CAGAAGCAGCTCCagaAGACTCTCCAAAG ^{3'}	A199S
oTM609	(F) 5'CCAATCTGGTTCCgctAATGCTCCTTGG ^{3'}	F227A
oTM610	(R) 5'CCAAGGAGCATTagcGGAACCAGATTGG ^{3'}	F227A
oTM611	(F) 5'GGAACCTCTTTGggaGTGAACTTTGGTC ^{3'}	S287G
oTM612	(R) 5'GACCAAAGTTCACTccCAAAGGAGTTCC ^{3'}	S287G
oTM613	(F) 5'GGATGAGGGTACAtggTTCCTTGTGggtGGAGCGCCTGG ^{3'}	A328W/Y332G
oTM614	(R) 5'CCAGGCGCTCCaccCACAAGGAAccaTGTACCCTCATCC ^{3'}	A328W/Y332G
oTM655	(F) 5'GGTTCCTTGTGgctGGAGCGCCTGG ^{3'}	Y332A
oTM656	(R) 5'CCAGGCGCTCCagcCACAAGGAACC ^{3'}	Y332A

6



7

8

1 **Supplementary Figure S1**

2


3

a. Scheme 1**b. Scheme 2**

1 **Supplementary Figure S2**

2

3



4